A Study of the Safety and Efficacy of Pancreatic Endocrine Cell Clusters Implanted Into the Omentum of Type 1 Diabetes Patients With Severe Hypoglycemia
Withdrawn before enrolling · Phase 1/Phase 2
Conditions studied: Diabetes Mellitus Type 1
In brief
This study will evaluate the safety, efficacy and durability of SR-02 administered to the omentum of patients of Type 1 diabetes with severe recurrent hypoglycemia. The study will also help establish the optimal treatment dose. Although this study is open to patients with all HLA or blood types, immunosuppression to prevent rejection will be required in this first in human study.
Key facts
- Study ID
- NCT06651515
- Run by
- Seraxis
- People needed
- 0
- Starts
- 2025-04-01
- Expected to finish
- 2028-03-01
- Last updated by the study team
- 2025-10-16
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Pennsylvania — Philadelphia, Pennsylvania, United States
- UPMC Presbyterian Shadyside — Pittsburgh, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.